ERLOTINIB TABLET 100MG & 150 MG

Listing ID #4203021

Get Latest Price

Packaging TypePlastic Bottle
UsageClinical, hospital etc.
CATEGORYAnti Cancer Tablets
FormTablets / Liquid / Capsules / Powder
Supply Type Manufacturer, Exporter, Supplier
Preferred Buyer Location All over the world

View More Details

Send Enquiry

Product Details

Packaging Type Plastic Bottle
Usage Clinical, hospital etc.
Storage Cool and Dry Place
Form Tablets / Liquid / Capsules / Powder
Storage Cool and Dry Place
Grade Standard Medicine Grade
Dosage 5mg
CATEGORY Anti Cancer Tablets

Erlotinib Tablet is indicated for:

The first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor(EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
The maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer, whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
The treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of at least one prior chemotherapy regimen.

3s corporation is Supplier,Exporter ,Wholesaler for Erlotinib Tablet 100mg & 150 mg in India.

We even offer contract manufacturing services from WHO GMP approved factories.

ADDITIONAL INFORMATION

Single oral doses of Erlotinib up to 1,000 mg in healthy subjects and weekly doses up to 1,600 mg in cancer patients have been tolerated. Repeated twice-daily doses of 200 mg single-agent Erlotinib in healthy subjects were poorly tolerated after only a few days of dosing. Based on the data from these studies, an unacceptable incidence of severe adverse reactions, such as diarrhea, rash, and liver transaminase elevation, may occur above the recommended dose.

SIDE EFFECTS-

MOST COMMON SIDE EFFECTS

Metastatic NSCLC – First-Line Treatment of Patients With EGFR Mutations:
- Most frequent (≥30%) adverse reactions were diarrhea, asthenia, rash, cough, dyspnea, and decreased appetite.
Advanced NSCLC – Maintenance Treatment:
- Rash and diarrhea.
- Rash (9%) and diarrhea (2%). Rash and diarrhea resulted in dose reductions or interruption (5% and 3%, respectively) and discontinuation (1% and 0.5%, respectively) of Erlotinib-treated patients.
Advanced NSCLC – Second/Third-Line Treatment:
- Rash and diarrhea.
- Rash (9%) and diarrhea (6%). Rash and diarrhea each resulted in dose reductions (6% and 1%, respectively) and discontinuation in 1% of Erlotinib-treated patients.
Advanced Pancreatic Cancer –Erlotinib Administered Concurrently with Gemcitabine:
- Fatigue, rash, nausea, anorexia, and diarrhea.
- Grade 3/4 (NCI-CTC Version 2.0) adverse reactions were rash (5%) and diarrhea (5%). Rash and diarrhea each resulted in dose reductions in 2% of patients and discontinuation in up to 1% of patients receiving Erlotinib plus gemcitabine.

Interested in this product? Ask for more details & Latest Price from seller

Send Enquiry

Company Details

3s corporation is one of india’s leading stockist, exporter & wholesaler for anti-cancer drug & oncology medicines. We even supply & export sex enhancement drugs, cardiac & anti diabetic medicines. We are a registered wholesaler & exporter for pharmaceutical products licensed by our fda and drug controller in india.